3.1 A medicine must not be promoted prior to the grant of the marketing authorization which permits its sale or supply.
3.2 The promotion of a medicine must be in accordance with the terms of its marketing authorization and must not be inconsistent with the particulars listed in its summary of product characteristics.
The legitimate exchange of medical and scientific information during the development of a medicine is not prohibited provided that any such information or activity does not constitute promotion which is prohibited under this or any other clause.
Clause 3 Promotion at International Meetings
The promotion of medicines at international meetings held in the UK may on occasion pose certain problems with regard to medicines or indications for medicines which do not have a marketing authorization in the UK although they are so authorized in another major industrialised country.
The display and provision of promotional material for such medicines is permitted at international meetings in the UK provided that the following conditions are met:
Clause 3.1 Advance Notification of New Products or Product Changes
Health authorities and health boards and their equivalents, trust hospitals and primary care trusts and groups need to estimate their likely budgets two to three years in advance in order to meet Treasury requirements and there is a need for them to receive advance information about the introduction of new medicines, or changes to existing medicines, which may significantly affect their level of expenditure during future years. At the time this information is required, the medicines concerned (or the changes to them) will not be the subject of marketing authorizations (though applications will often have been made) and it would thus be contrary to the Code for them to be promoted. Information may, however, be provided on the following basis:
i) the information must relate to:
(a) a product which contains a new active substance, or(b) a product which contains an active substance preparedin a new way, such as by the use of biotechnology, or(c) a product which is to have a significant addition to the existing range of authorized indications, or(d) a product which has a novel and innovative means of administration
ii) information should be directed to those responsible for making policy decisions on budgets rather than those expected to prescribe
iii) whether or not a new medicine or a change to an existing medicine is the subject of a marketing authorization in the UK must be made clear in advance informationiv) the likely cost and budgetary implications must be indicated and must be such that they will make significant differences to the likely expenditure of health authorities and trust hospitals and the like
v) only factual information must be provided which should be limited to that sufficient to provide an adequate but succinct account of the product’s properties; other products should only be mentioned to put the new product into context in the therapeutic area concerned
vi) the information may be attractively presented and printed but should not be in the style of promotional material – product specific logos should be avoided but company logos may be used; the brand name of the product may be included in moderation but it should not be stylised or used to excess
vii) the information provided should not include mock up drafts of either summaries of product characteristics or patient information leafletsviii)if requested, further information may be supplied or a presentation made.
Clause 3.2 Unauthorized IndicationsThe promotion of indications not covered by the marketing authorization for a medicine is prohibited by this clause.